U.S. ex rel. Demott v. Pfizer,
District of Massachusetts.
Firm attorneys represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 billion recovery for the federal and state governments.
U.S. ex rel. Graydon v. GlaxoSmithKline,
District of Massachusetts.
Firm attorneys served as lead counsel for whistleblowers alleging that GlaxoSmithKline (GSK) engaged in illegal promotion of the company’s popular asthma and Chronic Obstructive Pulmonary Disease (COPD) medication, Advair. The case culminated in a $1.04 billion recovery for the federal and state governments.
U.S. ex rel. Doghramji, et al. v. Community Health Systems Inc., et al.,
Middle District of Tennessee.
Firm attorneys represented three relators in a case alleging healthcare fraud by Tennessee-based company Community Health Systems, Inc. (“CHS”). The scheme to defraud the Medicare system jeopardized patients safety by unnecessarily hospitalizing patients and preventing patients suffering from true emergencies from receiving adequate care. CHS paid $97 million to resolve accusations that CHS emergency rooms in 120 hospitals systematically admitted patients not suffering from any emergency who should have been treated in an out-patient setting to capitalize on increased cost of reimbursement for emergency services and cheat federal and state insurance plans out of millions.
U.S. ex rel. McCoyd v. Abbott Laboratories,
Western District of Virginia.
The firm’s attorneys, in conjunction with state and federal governments, pursued claims against Abbot Laboratories, alleging that Abbot unlawfully marketed its anti-epileptic drug, Depakote, to children and nursing home patients. Their efforts on behalf of the lead whistleblower lead to a $1.6 billion recovery for federal and state governments, one of the largest recoveries under the False Claims Act in a pharmaceutical case involving a single drug, as well as the institution of a corporate integrity agreement that places compliance burdens on Abbott’s corporate management.
U.S. ex rel. Brown v. Celgene Corporation,
Central District of California.
GBB recovered $280 million in a non-intervened False Claims Act case against Celgene Corporation on the eve of trial. The Complaint alleged that Celgene unlawfully marketed its drugs Thalomid and Revlimid, including for unsafe and ineffective uses, and subverted independent judgment of medical professionals through false and misleading promotion. The Complaint also alleged that Celgene paid kickbacks to medical professionals to prescribe and recommend Celgene’s drugs in violation of the Anti-Kickback Statute. The settlement is the second largest in a non-intervened case brought under the False Claims Act.